pubmed.ncbi.nlm.nih.gov

The expression mechanism of programmed cell death 1 ligand 1 and its role in immunomodulatory ability of mesenchymal stem cells - PubMed

Review

The expression mechanism of programmed cell death 1 ligand 1 and its role in immunomodulatory ability of mesenchymal stem cells

Zhuo Chen et al. Chin J Traumatol. 2024 Jan.

Abstract

Programmed cell death 1 ligand 1 (PD-L1) is an important immunosuppressive molecule, which inhibits the function of T cells and other immune cells by binding to the receptor programmed cell death-1. The PD-L1 expression disorder plays an important role in the occurrence, development, and treatment of sepsis or other inflammatory diseases, and has become an important target for the treatment of these diseases. Mesenchymal stem cells (MSCs) are a kind of pluripotent stem cells with multiple differentiation potential. In recent years, MSCs have been found to have a strong immunosuppressive ability and are used to treat various inflammatory insults caused by hyperimmune diseases. Moreover, PD-L1 is deeply involved in the immunosuppressive events of MSCs and plays an important role in the treatment of various diseases. In this review, we will summarize the main regulatory mechanism of PD-L1 expression, and discuss various biological functions of PD-L1 in the immune regulation of MSCs.

Keywords: Immunomodulation; MSCs; PD-L1.

PubMed Disclaimer

References

1. Freeman G.J., Long A.J., Iwai Y., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027–1034. doi: 10.1084/jem.192.7.1027. - DOI - PMC - PubMed
1. Zhang J., Dang F., Ren J., et al. Biochemical aspects of PD-L1 regulation in cancer immunotherapy: (trends in biochemical sciences 43, 1014-1032; 2018) Trends Biochem Sci. 2019;44:557. doi: 10.1016/j.tibs.2019.03.004. - DOI - PMC - PubMed
1. Hudson K., Cross N., Jordan-Mahy N., et al. The extrinsic and intrinsic roles of PD-L1 and its receptor PD-1: implications for immunotherapy treatment. Front Immunol. 2020;11 doi: 10.3389/fimmu.2020.568931. - DOI - PMC - PubMed
1. Sun Y., Tan J., Miao Y., et al. The role of PD-L1 in the immune dysfunction that mediates hypoxia-induced multiple organ injury. Cell Commun Signal. 2021;19:76. doi: 10.1186/s12964-021-00742-x. - DOI - PMC - PubMed
1. Yan Y., Zhang L., Zuo Y., et al. Immune checkpoint blockade in cancer immunotherapy: mechanisms, clinical outcomes, and safety profiles of PD-1/PD-L1 inhibitors. Arch Immunol Ther Exp. 2020;68:36. doi: 10.1007/s00005-020-00601-6. - DOI - PubMed

The expression mechanism of programmed cell death 1 ligand 1 and its role in immunomodulatory ability of mesenchymal stem cells - PubMed